Long-term effectiveness, adherence and safety of twice-yearly paliperidone-palmitate long acting-injectable in patients with schizophrenia in Europe: 2-year mirror-image data from the paliperdone-2 per year study (P2Y).

Front Psychiatry · 2025 · PMC11913845 · PMID 40104335

Europe PMC DOI

hedged sentence

0.0710

closest p · 1.4× alpha

0.0710

boldest claim

The sentences

a statistical trendp=0.071so close (0.05 < p ≤ 0.1)

No differences were found in the previous treatment of the patients between subgroups though a statistical trend was noted in the proportion of patients treated previously with PP3M (86% inpatients vs . 66% outpatients, p=0.071).

also in 917 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.